New Kaiser Permanente research published February 21, 2022 in Nature Medicine shows that while Moderna COVID-19 vaccine protection is strong against coronavirus infection by the delta variant, it is not as strong against infection from the omicron variant.
There is a slightly elevated risk of intracranial thrombosis events following vaccination with the AstraZeneca ChAdOx1-S COVID vaccine, according to two new studies publishing February 22nd in PLOS Medicine.
Experts at Overlook are hoping that SurVaxM, a first-of-its-kind vaccine targeting a protein found in glioblastomas and other cancers, will give patients a better shot at long-term survival and improved function.
The researchers found that the level of protection from SARS-CoV-2 infection fell by about 21 percentage points, on average, in the interval from one to six months after full vaccination—whereas the level of protection against severe COVID-19 fell by only about 10 percentage points in the same interval.
A new study suggests that a single bout of exercise does not change the immune response to a coronavirus booster shot in people with rheumatic autoimmune diseases. The article is published ahead of print in the Journal of Applied Physiology.
Artificial intelligence has aided one Michigan State University researcher and his team in finding answers about the new omicron variant. The MSU researchers report omicron and other variants are evolving increased infectivity and antibody resistance according to an artificial intelligence model. Therefore, new vaccines and antibody therapies are needed, the researchers say.
The SARS-CoV-2 virus is continuously evolving and structural changes to the virus may impact the efficacy of antibody therapies and vaccines. A study publishing February 17th in PLOS Pathogens by Anshumali Mittal at the University of Pittsburgh, USA and colleagues describes the structural and functional landscape of neutralizing antibodies against SARS-CoV-2 spike protein and discuss the effects of mutations on the virus spike protein that may allow it to evade antibody responses.
Using powerful tools and techniques developed in the field of structural biology, researchers at the University of Washington and The Scripps Research Institute have discovered new details about the human immunodeficiency virus, HIV.
Researchers at Mayo Clinic, along with colleagues in the Netherlands and Germany, may have a viable, less risky alternative to regenerate bone: messenger RNA. This well-known platform for vaccines has already proven to be safe in human use by the FDA.
A future vaccine providing protection against a wide range of coronaviruses that jump from their original animal hosts to humans — including SARS-CoV-2, the cause of COVID-19 — may be possible, say Johns Hopkins Medicine researchers, based on findings from their recent study.
Next generation mRNA vaccines. A new PSMA-targeted approach for prostate cancer. A novel treatment for reducing LDL cholesterol. These are some of the innovations that will optimize and change healthcare in the coming year, according to an expert panel of clinicians and researchers.
Cleveland Clinic has announced the Top 10 Medical Innovations for 2022. The list of breakthrough technologies was selected by a committee of Cleveland Clinic subject matter experts, led by D. Geoffrey Vince, Ph.D., executive director of Innovations and chair of Biomedical Engineering at Cleveland Clinic.
Researchers reporting in ACS Infectious Diseases have developed a new type of cholera vaccine consisting of polysaccharides displayed on virus-like particles. The vaccine generated long-lasting antibody responses against V. cholerae in mice.
African children and adolescents hospitalized with COVID-19 experience much higher mortality rates than Europeans or North Americans, according to a study conducted by the Institute of Human Virology at the University of Maryland School of Medicine and the Institute of Human Virology Nigeria.
Researchers at the Tufts University School of Engineering are building a reputation for precision targeting in drug delivery. Their tools: tiny lipid-based nanoparticles (LNPs) that can be fine tuned to latch on to specific tissues, organs, even cell types within the body. Their latest creation: LNPs that carry genetic instructions directly into the lungs.
People who think they know a lot about COVID-19 vaccines are more likely to hold vaccine misperceptions, according to a new survey from a nationwide coalition of university-based researchers.
A Kaiser Permanente study published Feb. 14, 2022, in The Lancet Regional Health – Americas found that one month after a third dose, the Pfizer-BioNTech COVID-19 vaccine effectiveness is higher for preventing infection and hospitalization than 2 doses of the vaccine after 1 month.
Asymptomatic COVID infection in generally healthy unvaccinated adults is likely much less common than previously reported, according to a new study published Feb. 14 in Open Forum Infectious Diseases by researchers at the Uniformed Services University of the Health Sciences (USU).
Antibodies elicited by COVID-19 vaccination become steadily more powerful for at least six months after vaccination, according to a study by researchers at Washington University School of Medicine in St. Louis that involved the Pfizer-BioNTech COVID-19 vaccine.
Chulalongkorn University reaffirms its commitment to “Innovations for Society”, which aims at developing innovations that address social issues and creating a better society in all aspects, including health, well-being and knowledge in order to move society forward. Let’s find out more about Chulalongkorn University’s amazing innovations.
Cancer patients undergoing active treatment were more likely to believe misinformation related to COVID-19 than those without a history of cancer, according to a new study led by researchers at Virginia Commonwealth University.
Participants in the study who cycled on a stationary bike or took a brisk walk for an hour-and-a-half after getting a flu shot or COVID-19 jab produced more antibodies in the following four weeks compared to participants who sat or continued with their daily routine post-immunization.
• Results from a study from France suggest that both individual and herd vaccine-induced immunity protect against severe forms of COVID-19 in patients on dialysis.
• A U.S. study found that antibody responses following COVID-19 vaccination wane over time across vaccine types in patients on dialysis.
The World Health Organization (WHO) is supporting African companies to make a covid vaccine. But today, in an article co-published with German newspaper Die Welt, The BMJ can reveal that a foundation representing vaccine maker BioNtech has been accused of seeking to undermine this initiative.
A number of existing strains of SARS-CoV-2, as well as other future variants that could arise, have the potential to escape the immune system’s cytotoxic T cell response in some portion of the population. That’s the conclusion of a new modeling study publishing February 10th in PLOS Computational Biology.
Scientists at McMaster University who have developed an inhaled form of COVID vaccine have confirmed it can provide broad, long-lasting protection against the original strain of SARS-CoV-2 and variants of concern.
The research, recently published in the journal Cell, reveals the immune mechanisms and significant benefits of vaccines being delivered directly into the respiratory tract, rather than by traditional injection.
People with cancer are often given immunosuppressive treatments that weaken their innate immune defences. This puts them at high risk of severe disease, should they become infected by Coronavirus.
A new study by UCLA researchers and colleagues demonstrates that the Ebola vaccine known as rVSVΔG-ZEBOV-GP results in a robust and enduring antibody response among vaccinated individuals in areas of the Democratic Republic of Congo (DRC) that are experiencing outbreaks of the disease. Among the more than 600 study participants, 95.6% demonstrated antibody persistence six months after they received the vaccine.
The study is the first published research examining post–Ebola-vaccination antibody response in the DRC, a nation of nearly 90 million. While long-term analyses of the study cohort continue, the findings will help inform health officials’ approach to vaccine use for outbreak control, the researchers said.
Researchers at Fox Chase Cancer Center conducted the largest published, peer-reviewed, study to-date examining the short-term adverse effects of mRNA COVID-19 vaccination in patients with cancer—finding they experienced no more, and no different, side effects compared to non-cancer patients.
Ao longo da pandemia de COVID-19, um erro comum é que as crianças não são afetadas pela doença, e que se elas ficassem doentes, os sintomas seriam leves. Porém, a pandemia está afetando as crianças de maneiras diversas, física e mentalmente.
مدينة روتشستر، ولاية مينيسوتا- طوال جائحة فيروس كورونا المستجد (كوفيد-19)، كان هناك اعتقاد خاطئ شائع مفاده أن الأطفال لا يتأثرون كثيرًا بفيروس كورونا المستجد (كوفيد-19)، وإذا أصيبوا بالمرض، ستكون أعراضهم خفيفة. إلا إن الجائحة تؤثر على الأطفال من نواح كثيرة، جسديًا وعقليًا.
Researchers at the University of Chicago Medicine found that when searching for vaccine information online, Spanish language resources took extra clicks to access compared to English language resources.
CSUDH is partnering with Rite Aid to bring this vaccination clinic to campus to make it easier for everyone to get vaccinated and stop the spread of COVID-19.
Roswell Park Comprehensive Cancer Center is the first center to treat patients in a newly opened advanced-stage clinical trial utilizing the brain cancer vaccine SurVaxM, offering a new treatment option for patients who are dealing with a rare but deadly form of the disease. The multicenter randomized clinical trial is sponsored by MimiVax LLC, a company spun off from Roswell Park in 2012.
A one-year, $10.3 million dollar grant from the U.S. Health Resources and Services Administration (HRSA) was awarded to increase COVID-19 vaccinations through the development and mobilization of existing community-based health and outreach workforces in the state by The University of Texas Health Science Center at Houston (UTHealth Houston).
Wistar Institute scientists take a promising step in the direction of developing an HIV vaccine that uses a unique native-like trimer to develop Tier-2 neutralizing antibodies—the kind that matter for combatting HIV—in mice for the first time.
On July 15, 2021, the U.S. Surgeon General issued an urgent plea for all Americans to take part in slowing a serious threat to public health. He wasn’t talking about the COVID-19 pandemic but rather the harmful effects on personal and public health caused by the infodemic – the creation and spread of an excessive amount of unreliable and false health information.
Theodore Beauchaine and his colleagues break down the cognitive shortcuts that can affect how we assess risk and decide to behave in the face of the pandemic in a recent paper in the journal Brain, Behavior, and Immunity.
As COVID-19 edges from pandemic to endemic status, there is a growing need for antiviral therapies. A team of UF researchers has identified dozens of therapeutic targets that could feed the drug development pipeline.
Fathers older than age 34 were more open to having their child vaccinated against COVID-19, while younger Black and white mothers were the least open to it, finds a new survey of Medicaid recipients from the Brown School at Washington University in St. Louis.
Researchers at McMaster University have found that children who receive years of season-specific flu vaccines develop antibodies that also provide broader protection against new strains, including those capable of causing pandemics.
The Innovative Genomics Institute, founded by Nobel Laureate Jennifer Doudna, is partnering with Mobility Health to bring rapid PCR-based testing to migrant workers and their families in the Salinas Valley region of Northern California. Mobile service will provide COVID testing, vaccines and wraparound services.
People from racial and ethnic minorities in the United States and the United Kingdom were up to three times as likely to report being unsure or unwilling to get a COVID-19 vaccine during the initial vaccine rollout compared to white participants, found a study published in Nature Communications.
For several hours on Monday, January 31, 2022, a misleading article from news agency Reuters lead to many readers sharing the report on social media as conclusive evidence of ivermectin’s effectiveness against COVID-19, and proof of the alleged conspiracy of suppressed research to blame for the anti-parasite drug’s current lack of approval by the United States Food & Drug Administration.